{"links":{"feed":"https://www.erudio.com/reports/quilt-3-055-nct03228667/feed.json","html":"https://www.erudio.com/reports/quilt-3-055-nct03228667","json":"https://www.erudio.com/reports/quilt-3-055-nct03228667.json","markdown":"https://www.erudio.com/reports/quilt-3-055-nct03228667.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"quilt-3-055-nct03228667"}},"request":"https://www.erudio.com/contact?report=quilt-3-055-nct03228667"},"offer":{"cited_clinicians":5,"cited_commentary_sources":13,"verified_hcp_statements":91,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":5},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"quilt-3-055-nct03228667"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=quilt-3-055-nct03228667","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/quilt-3-055-nct03228667","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 91 verified statements · 52 from 5 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T14:52:19.264259Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1."},{"claim_count":18,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":7,"title":"Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ"},{"claim_count":17,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":11,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":11,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":3,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":16,"coverage":"discussed","id":"A1","source_count":6,"title":"Practice readiness, evidentiary sufficiency and access expectations"},{"claim_count":20,"coverage":"discussed","id":"A2","source_count":2,"title":"Broader lymphocyte-restoration rationale and proposed supportive-care work-up"},{"claim_count":9,"coverage":"discussed","id":"A3","source_count":5,"title":"Confirmatory comparator choices and transfer across combinations"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":1,"title":"Community delivery, research-stage cellular combinations and selective chemotherapy"},{"claim_count":9,"coverage":"discussed","id":"A5","source_count":5,"title":"Public interpretation of survival tails, subgroups and anticipated updates"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":26,"cited_clinicians":5,"cited_clinicians_by_role":{"physician":4,"physician, Hematology and oncology":1},"cited_physicians":5,"cited_sources":13,"claims_by_expression_type":{"comparison":8,"experience":4,"interpretation":20,"opinion":31,"question":4,"restatement":8,"uncertainty":3,"unspecified":13},"claims_by_kind":{"source_observation":91},"clinician_statements":52,"evidence_units":58,"findings":10,"organisational_accounts":3,"people_cited":8,"people_identity_verified":5,"people_total":9,"screened_sources":26,"verified_claims":91},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":1,"questions":1,"restated":1,"views":7},"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":4,"passages":7,"sources":2,"sources_by_kind":{"media":2}},"title":"Checkpoint rescue: where clinicians split on readiness for routine use","title_holders":{"cited_claim_ids":["claim-bea6b73a086ec475eead","claim-db666436adf385b54a73","claim-7bd98fda785bcdbe1257","claim-ca0004517cecddd72e22"],"clinicians":true,"holders":3,"sides":[{"cited_claim_ids":["claim-bea6b73a086ec475eead"],"holders":1},{"cited_claim_ids":["claim-db666436adf385b54a73","claim-7bd98fda785bcdbe1257","claim-ca0004517cecddd72e22"],"holders":2}],"speakers":4,"view":"split"},"evidence_line":"11 statements from 4 speakers in 2 sources, all podcasts or videos","holder_line":"3 of the 4 named speakers in this finding take a side on this question: 1 on one side, 2 on the other; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":0,"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":4,"restated":1,"views":4},"limitations":2,"links":{"context":0,"support":13},"ma_question":true,"named_voices":1,"passages":11,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Nogapendekin alfa inbakicept: why a speaker questions value beyond ICI rechallenge","title_holders":{"cited_claim_ids":["claim-952e5b1b5e12110729da","claim-5e485292e23133fd8557","claim-b54e66181809b2b3f092","claim-dd61340d6150a5e8f55f","claim-db53ed9d909a4d29e6f5","claim-97b03dde0a9d5dccc82a","claim-4fab490a02b4fdcc7150","claim-49389af6192060dfdfda"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"11 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":1,"id":"F3","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":9},"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":2,"passages":11,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"ALC recovery: where speakers split on what the survival association means","title_holders":{"cited_claim_ids":["claim-8bb576c34e072722e489","claim-76242acb9d92514427bc","claim-0d9abf05231fbcc71368","claim-95b8fa2c6228c9b2002a","claim-bcff60b9dbe75b5dbf62","claim-0da329d6e1b110b13ca6","claim-f60db2343b11362c495d","claim-07a3b055884fc07ae4be","claim-9610fcdc22dad70dfa9a","claim-dd61340d6150a5e8f55f"],"clinicians":false,"holders":2,"sides":[{"cited_claim_ids":["claim-8bb576c34e072722e489","claim-76242acb9d92514427bc","claim-0d9abf05231fbcc71368","claim-95b8fa2c6228c9b2002a","claim-bcff60b9dbe75b5dbf62","claim-0da329d6e1b110b13ca6","claim-f60db2343b11362c495d","claim-07a3b055884fc07ae4be","claim-9610fcdc22dad70dfa9a"],"holders":1},{"cited_claim_ids":["claim-dd61340d6150a5e8f55f","claim-f60db2343b11362c495d","claim-07a3b055884fc07ae4be","claim-9610fcdc22dad70dfa9a"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"12 statements from 2 speakers in 5 sources, 1 of them a podcast or video","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other"},{"cited_clinicians":0,"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":7},"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":1,"passages":10,"sources":2,"sources_by_kind":{"commentary":2}},"title":"ALC–survival framing: why a speaker challenges its timing and interpretation","title_holders":{"cited_claim_ids":["claim-972072c225206f1b09fd","claim-ea379b37036d157ad5ec","claim-f60db2343b11362c495d","claim-dd61340d6150a5e8f55f"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"10 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":3,"id":"F5","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":3,"views":7},"limitations":2,"links":{"context":0,"support":14},"ma_question":true,"named_voices":4,"passages":12,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"US lung access: where speakers split on approval before phase 3 confirmation","title_holders":{"cited_claim_ids":["claim-db666436adf385b54a73","claim-b6c81202b76d5c2f4141","claim-0e257b87bbcabd6dd240","claim-ec24ef5a7178c8b5b8cf","claim-af38a71e18d1b90cb12c","claim-1ddfd1f3eb1f6b84819c","claim-c69662f61e9cd011d8cd"],"clinicians":false,"holders":4,"sides":[{"cited_claim_ids":["claim-db666436adf385b54a73","claim-b6c81202b76d5c2f4141","claim-0e257b87bbcabd6dd240","claim-ec24ef5a7178c8b5b8cf"],"holders":3},{"cited_claim_ids":["claim-af38a71e18d1b90cb12c","claim-1ddfd1f3eb1f6b84819c","claim-c69662f61e9cd011d8cd"],"holders":1}],"speakers":4,"view":"split"},"evidence_line":"12 statements from 4 speakers in 4 sources, 1 of them a podcast or video","holder_line":"4 of the 4 named speakers in this finding take a side on this question: 3 on one side, 1 on the other"},{"cited_clinicians":0,"id":"F6","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":1,"views":7},"limitations":3,"links":{"context":0,"support":9},"ma_question":false,"named_voices":2,"passages":7,"sources":5,"sources_by_kind":{"commentary":5}},"title":"QUILT-3.055: what speakers say","evidence_line":"9 statements from 2 speakers in 5 sources"},{"cited_clinicians":3,"id":"F7","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":3,"passages":4,"sources":1,"sources_by_kind":{"media":1}},"title":"Side-effect impressions: what clinicians highlight from pooled experience","title_holders":{"cited_claim_ids":["claim-e77816586af5ea976291","claim-eb58a12e22b5a3833168","claim-7b9163567013813cf8ec"],"clinicians":true,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"5 statements from 3 speakers in 1 source, a podcast or video","holder_line":"3 of the 3 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F9","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":2,"questions":2,"restated":2,"views":4},"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":3,"passages":9,"sources":5,"sources_by_kind":{"commentary":3,"media":2}},"title":"Further trials: where speakers split on confirmation using new ICI combinations","title_holders":{"cited_claim_ids":["claim-b6c81202b76d5c2f4141","claim-5e485292e23133fd8557","claim-4fab490a02b4fdcc7150","claim-42ab6afda7b24fa3556e","claim-d3717f2ba2d779d1125b","claim-1900b46a97f3b3c27f12","claim-af38a71e18d1b90cb12c","claim-49389af6192060dfdfda"],"clinicians":false,"holders":3,"sides":[{"cited_claim_ids":["claim-b6c81202b76d5c2f4141","claim-5e485292e23133fd8557","claim-4fab490a02b4fdcc7150","claim-42ab6afda7b24fa3556e","claim-d3717f2ba2d779d1125b","claim-1900b46a97f3b3c27f12"],"holders":2},{"cited_claim_ids":["claim-af38a71e18d1b90cb12c","claim-49389af6192060dfdfda"],"holders":1}],"speakers":3,"view":"split"},"evidence_line":"10 statements from 3 speakers in 5 sources, 2 of them podcasts or videos","holder_line":"3 of the 3 named speakers in this finding take a side on this question: 2 on one side, 1 on the other"},{"cited_clinicians":3,"id":"F8","population":"beyond","structure":{"claims":21,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":7,"views":11},"limitations":3,"links":{"context":2,"support":25},"ma_question":true,"named_voices":3,"passages":14,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Immune restoration: clinicians see potential; one needs RCT outcome data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-ca0004517cecddd72e22","claim-d1be9d52ef4b975d19e3"],"clause":"one needs RCT outcome data","holders":1},"cited_claim_ids":["claim-86e0741db5ed5015f59f","claim-46d1bceb57fc2c9bb1b4","claim-c052afdb2121851a1f59","claim-d901585faabe2803907d","claim-8d1d6debece1bd8eb080","claim-7bd98fda785bcdbe1257","claim-f1f7d913685d122eb290","claim-82d987ab2d5317bd0b29","claim-72f8cb3a991ecdb1da1d","claim-ca0004517cecddd72e22","claim-19382c4968b8e7f74fa7","claim-d1be9d52ef4b975d19e3"],"clinicians":true,"holders":3,"speakers":3,"view":"reading"},"evidence_line":"21 statements from 3 speakers in 2 sources, 1 of them a podcast or video","holder_line":"3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one needs RCT outcome data”"},{"cited_clinicians":2,"id":"F10","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":3,"views":3},"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":2,"passages":6,"sources":1,"sources_by_kind":{"media":1}},"title":"Local care: clinicians favor it; one proposes cells with chemo","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-a07f0b5c34fe2a515463","claim-cb3418e07e9377f2f8e5"],"clause":"one proposes cells with chemo","holders":1},"cited_claim_ids":["claim-28d8cd46ccbe91b030c3","claim-563b2f3207ba1399270b","claim-466df8ca2d1e15e929dd","claim-10d2a2d9e7c149b1d0dc"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 1 source, a podcast or video","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one proposes cells with chemo”"}],"open_question":{"basis":"From finding F1 (11 statements from 4 speakers in 2 sources)","cited_claim_ids":["claim-9c6b56cbed03b0145e16","claim-db666436adf385b54a73","claim-7bd98fda785bcdbe1257","claim-be51af50ecc6ff7186c0","claim-bea6b73a086ec475eead","claim-ca0004517cecddd72e22","claim-7076a236414f6fabd38c","claim-9a3907568941a22e8f01","claim-be6face0d2aca6290ffb","claim-4938c32dc0e610033c9c","claim-d3717f2ba2d779d1125b"],"finding_ids":["F1"],"question":"What randomized evidence on long-term survival and patient-centered outcomes do clinicians say they need before routinely adding N-803 to checkpoint inhibition for NSCLC progressing on checkpoint therapy, as studied in QUILT-3.055?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Whether checkpoint-rescue observations support routine use"},{"id":"section-2","level":2,"title":"One X account challenges added benefit and asks about harm; another rejects cross-study causal conclusions"},{"id":"section-3","level":2,"title":"One clinician and the sponsor emphasize ALC recovery; an X account treats the survival relationship as hypothesis-generating"},{"id":"section-4","level":2,"title":"Whether later ALC endpoint emphasis changes confidence in the survival interpretation"},{"id":"section-5","level":2,"title":"Clinicians balance faster access with confirmation; one X account disputes near-term US lung availability"},{"id":"section-6","level":2,"title":"X accounts emphasize survival tails and selected subgroups; one cautions against treating a subgroup median as the overall result"},{"id":"section-7","level":2,"title":"Two hosts perceive favorable tolerability, while one clinician describes pooled rather than trial-specific safety experience"},{"id":"section-8","level":2,"title":"Clinicians welcome further trials; one X account questions transfer of evidence across checkpoint combinations"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"Speakers find broad immune restoration attractive, while distinguishing biological rationale from demonstrated cancer benefit"},{"id":"section-11","level":3,"title":"Two clinicians prioritize community outpatient access; one proposes cellular combinations without abandoning chemotherapy"},{"id":"section-12","level":2,"title":"Scope and coverage of these sources"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2}],"id":"T1","label":"Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1."},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":11},{"id":"F4","shared_claims":10},{"id":"F6","shared_claims":4}],"id":"T2","label":"Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":8},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":5},{"id":"F9","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":5},{"id":"F6","shared_claims":3},{"id":"F9","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":9},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F9","shared_claims":3}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":5}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T14:52:19.264259Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T17:36:34Z","record_hash":"5fb52b92043a2c9fa6daa6c97edff8f8b293fd9f782c0b048c29c4ad9d6c1c62","release_hash":"a2824803ceff4d2931dbf777cbdd9cf7ec1573e5bd342913d2d34121903b712e","report_id":"erudio-nct03228667","run_id":"60ee6423-4bc2-436d-97b9-40eb002f965a","schema_version":"5.0","slug":"quilt-3-055-nct03228667","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"For QUILT-3.055, a hematology-oncology physician who describes presenting the update and helping develop the approach interprets responses as a signal of renewed checkpoint activity, but another physician wants randomized long-term survival and patient-centered evidence. A physician described in the sources as reporting their own results considers survival observations sufficient for faster access. Anktiva’s contribution beyond continued checkpoint inhibition remains disputed; the ALC–survival association does not prove that lymphocyte restoration causes benefit.","examples":[],"meta_description":"26 sources screened · 91 verified statements (52 from clinicians verified by NPI or staff page) from 13 sources · 10 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T17:36:34Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-20T19:35:09Z","kind":"routine","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":26},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 57 sources about other trials or topics are not included; 37 sources that may describe the trial without naming it were not read.","The sources reviewed for this edition do not represent all HCPs or establish how common any view is; repeated posts and source totals are not independent clinician counts.","Potentially relevant discussion that did not name the trial was not all read. Unnamed references and alternative transcriptions may therefore be missing.","No full protocol or exact-trial results publication was found among the sources reviewed. Descriptions of peer-review submission do not establish completed publication.","Clinical roles are not established for several named or pseudonymous X accounts. Their statements are distinguished from clinician interviews and organizational commentary.","Some remarks on the Oncology Brothers episode cannot be assigned to a named speaker and cannot be counted as additional independent agreement or disagreement.","Survival figures refer to differing cohort descriptions, biomarker thresholds and analysis dates. They cannot be treated as interchangeable estimates or pooled into a comparative effect.","The detailed safety account concerns pooled exposure rather than a QUILT-3.055 adverse-event table; favorable impressions do not establish absence of other toxicity or comparative safety.","Exact combination labels, reimbursement decisions and the regulatory allegations discussed by accounts were not established by the sources reviewed.","Later descriptions of confirmatory regimens and comparators differ. They do not establish that all proposed studies test the same combination or isolate the same component effect."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":11,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":13},"count":13,"evidence_window":{"end":"2026-11-04","start":"2024-04-26"},"retrieval_snapshot":"2026-11-20T09:40:40.204327Z","timeline":[{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2025-W52"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W27"},{"count":2,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W45"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT03228667:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03228667:context","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:39f2d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783891130293100855:fb531c1f-195d-46b7-ae1b-7c6e3474555d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783941602706444724:31b94adc-6866-4ae6-8e82-c0c492650f7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783945483070877876:1b30b5d7-d8bf-451e-8dd3-a5756fc0adf1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1784006691626819808:8a650e21-0745-4d3d-8ea2-311e6f135963","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1784392992901484554:a72d3e81-dbbc-4707-a2e3-e48457a42bff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1784784192343265397:584d1d91-74e1-432d-9a8e-5ae3f64f7434","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1784948538981425412:0a001e9f-0702-433a-99f3-f68712b54fd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833129210262819108:a5fe4c82-c27e-4420-9496-817cc49f5ea6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833509203362910444:9774e9d0-184e-428b-a2d3-559e79a3a8a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965043802164654466:3d8002eb-3e78-481b-8989-952708b620dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001712154299502977:5d0c2f06-ac56-46c1-a8ff-bc561b903c3d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011071874038632821:5fa3d9eb-641a-4486-999b-a9e415df3ceb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011083061459579075:3cac3ba7-1f8e-4f48-86d3-e1629ab8df25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011453457786359812:b442947a-0570-4bb1-b579-81329685eb4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2020131485987045792:a9a69363-1114-497c-8914-dd85a701b525","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2029466955720094107:77cba32e-e975-4d33-a282-c07f0cef63ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056733452087529592:2cb10556-9ccc-4de7-bdfd-e6590292cbb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073178803946528977:93e746f6-e95a-44fe-955d-466b80107799","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110714722060476570:b1a6440b-7c79-40d5-af3d-8568f3429bd4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2111833995201622052:fab2edf0-77b3-477d-a81b-c0b5663d9be9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117870710685348054:5abf8934-59b2-4e58-bc96-64757e31214e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:889850623377764353:91a33f79-26e5-43f2-af12-26e5310d143b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:889850801346281476:2eba8a7e-12cb-4b21-b6e1-eec4a9a30095","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:890113479943888897:43a21063-6bb4-4d6a-b43d-37361e564c25","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mUnJfRuyLWs","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":24,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":26},"count":26,"evidence_window":{"end":"2026-11-04","start":"2017-07-25"},"retrieval_snapshot":"2026-11-20T09:40:40.204327Z","timeline":[{"count":3,"week":"2017-W30"},{"count":5,"week":"2024-W17"},{"count":2,"week":"2024-W18"},{"count":2,"week":"2024-W37"},{"count":1,"week":"2024-W39"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2025-W52"},{"count":3,"week":"2026-W03"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W10"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W27"},{"count":2,"week":"2026-W42"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":46,"publication":0,"registry":0,"regulatory":0,"x_thread":38,"x_video":0,"youtube":7}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Anktiva"],"label":"nogapendekin alfa inbakicept","slug":"nogapendekin-alfa-inbakicept"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":["Tecentriq"],"label":"atezolizumab","slug":"atezolizumab"},{"brand_names":["Bavencio"],"label":"avelumab","slug":"avelumab"},{"brand_names":["Imfinzi"],"label":"durvalumab","slug":"durvalumab"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"PD-L1 t-haNK","slug":"pd-l1-t-hank"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Small cell lung cancer","slug":"small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Head and neck squamous cell carcinoma","slug":"head-and-neck-squamous-cell-carcinoma"},{"reason":"Unmapped registry condition: Merkel Cell Carcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Melanoma","slug":"melanoma"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"},{"reason":"Unmapped registry condition: Gastric Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Cervical Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Hepatocellular carcinoma","slug":"hepatocellular-carcinoma"},{"reason":"Unmapped registry condition: Microsatellite Instability","status":"unmapped"},{"reason":"Unmapped registry condition: Mismatch Repair Deficiency","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"QUILT-3.055","aliases":["QUILT-3.055","CA-ALT-803-02-17","QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors"],"brief_title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer","Small Cell Lung Cancer","Urothelial Carcinoma","Head and Neck Squamous Cell Carcinoma","Merkel Cell Carcinoma","Melanoma","Renal Cell Carcinoma","Gastric Cancer","Cervical Cancer","Hepatocellular Carcinoma","Microsatellite Instability","Mismatch Repair Deficiency","Colorectal Cancer"],"display_condition":"cancer previously treated with immune checkpoint inhibitors","display_interventions":[["nogapendekin alfa inbakicept (N-803)","pembrolizumab"],["nogapendekin alfa inbakicept (N-803)","pembrolizumab","PD-L1 t-haNK"],["nogapendekin alfa inbakicept (N-803)","pembrolizumab","docetaxel"]],"enrollment":{"count":40,"type":"ESTIMATED"},"interventions":[{"name":"N-803 + Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Nivolumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Atezolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Avelumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Durvalumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Pembrolizumab + PD-L1 t-haNK","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Nivolumab + PD-L1 t-haNK","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Atezolizumab + PD-L1 t-haNK","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Avelumab + PD-L1 t-haNK","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Durvalumab + PD-L1 t-haNK","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Docetaxel + Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"N-803 + Docetaxel + Nivolumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT03228667","official_title":"QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2029-08-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"ORR reflects tumor shrinkage and is the key measure of antitumor activity.","measure":"ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.","timeFrame":"Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods"},{"description":"OS is the gold-standard efficacy endpoint; the protocol explores whether an ALC rise predicts a survival benefit.","measure":"Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ","timeFrame":"Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes"}],"registered_date":{"date":"2017-07-25","type":"ACTUAL"},"registry_last_updated":"2026-01-14","registry_url":"https://clinicaltrials.gov/study/NCT03228667","short_name":"QUILT-3.055","short_name_basis":"canonical_name","sponsor":"ImmunityBio, Inc.","start_date":{"date":"2018-12-11","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"CA-ALT-803-02-17","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}